Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

BAY 94-9027 (damoctocog alfa pegol, Jivi) is an extended-half-life recombinant factor VIII (rFVIII) shown to be well-tolerated and efficacious in bleeding prevention in previously treated patients with severe hemophilia A. During the PROTECT VIII study, prophylaxis patients received BAY 94-9027 at i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancuso, Maria Elisa, Reding, Mark T., Negrier, Claude, Kerlin, Bryce A., Rangarajan, Savita, Simpson, Mindy L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322588/
https://www.ncbi.nlm.nih.gov/pubmed/33296943
http://dx.doi.org/10.1055/a-1333-5536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322588/
https://www.ncbi.nlm.nih.gov/pubmed/33296943
http://dx.doi.org/10.1055/a-1333-5536

Ejemplares similares